Clinical trial · Observational
The Impact of Ureteral Stents on Peristalsis
NCT01739738CI-TRIAL-00044218withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study did not start
Summary
Brief summary (as posted)
The purpose of the study is to investigate the impact of ureteral stents on the functioning of ureteral peristalsis (normal contractions in the ureteral organ muscle).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hydronephrosis | — | UNRESOLVED | — |
| Kidney Stones | — | UNRESOLVED | — |
| Tumor | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ureteral Stent | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- no Ureteral Stent - control group
- description
- non-stented volunteers to receive ultrasound for peristalsis changes detection
- label
- Ureteral stent
- description
- patients who receive stent, and to receive ultrasound for peristalsis changes detection in their stented and non-stented ureter
- interventionNames
- Device: Ureteral Stent
Primary outcomes (1)
- measure
- Effect of stent on ureteral peristalsis in stented ureter
- timeFrame
- before and after stent insertion (approximately 30 minutes)
- description
- before and after stent insertion (approximately 30 minutes)
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: 1. stone disease 2. localized tumor disease 3. hydronephrosis of unknown ethiology 4. patients who receive a prophylactic stent before a planned operation. Exclusion Criteria: 1. Patients being septic and in a life-threatening condition before or after stent-insertion 2. patients with tumors in a progressive state that affect the retroperitoneum (contralateral ureter might be affected and can not serve as a control for the stented side) 3. patients with Morbus Ormond (same reason as above) 4. patients requiring ureteral stents bilaterally (same reason as above) 5. long-term stented patients will be excluded as we are interested in evaluating the onset of changes in peristalsis rate which are expected to be most significant in an acute setting. 6. patients with preexisting abnormalities/pathologies of the urinary tract e.g. reflux disease, megaureter or bladder dysfunctions as these will likely affect our results 7. non English-speaking patients will be excluded as they will not be able to understand the letter of consents. Exclusion criteria for control group: 1. known preexisting pathology in the urinary tract (see above) 2. volunteers who underwent previous surgical procedures on kidney, ureter or bladder within the past 5 years as this may change the starting position of our study 3. patients currently taking an α-blocker (alfuzosin, terazosin, doxazosin, tamsulosin, prazosin) because these medications are known to affect peristalsis 4. patients currently taking calcium channel blocker (verapamil, diltiazem, nifedipine, nicardipine, bepridil, mibefradil) because these medications are known to affect peristalsis
References
Publications (0)
Data not yet available
No reference posted for this study.